Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate

Journal of Medical Microbiology

Volumn 55, Issue 10, 2006, Pages 1441-1446

  Kashef, Nasim ^a   Behzadian Nejad, Qorban ^a   Najar Peerayeh, Shahin ^a   Mousavi Hosseini, Kamran ^b   Moazzeni, Mohammad ^a   Djavid, Gholamreza Esmaeeli ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; ADIPIC ACID DERIVATIVE; ADIPIC ACID DIHYDRAZIDE; ALCOHOL; ALGINIC ACID; BACTERIAL ANTIGEN; CARRIER PROTEIN; EXOPOLYSACCHARIDE; IMMUNOGLOBULIN G; NUCLEASE; POLYMER; PROTEINASE; PYROGEN; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; SEPHAROSE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BRONCHUS MUCUS; CHROMATOGRAPHY; CONTROLLED STUDY; CYSTIC FIBROSIS; DETERIORATION; DIALYSIS; DRUG CONJUGATION; DRUG SYNTHESIS; FEMALE; IMMUNIZATION; IMMUNOGENICITY; LUNG FUNCTION; MORTALITY; MOUSE; NONHUMAN; OPSONIZATION; PHENOTYPE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; TOXICITY TESTING;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; FEMALE; GLYCOSAMINOGLYCANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; POLYMERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TETANUS TOXOID; VACCINATION; VACCINES; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 33750428189     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46696-0     Document Type: Article

References (28)

1. Barington, T., Gyhrs, A. & Kristensen, K. (1994). Opposite effects of actively and passively aquired immunity to the carrier on responses of human infants to Haemophilus influenza type b conjugate vaccine. Infect Immun 62, 9-14.
2. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of the microgram quantity of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
3. Cryz, S. J., Furer, E., Jr & Que, J. U. (1991). Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun 59, 45-50.
4. Doggett, R. G., Harrison, G. M., Stillwell, R. N. & Wallis, E. S. (1966). An atypical Pseudomonas aeruginosa associated with cystic fibrosis of the pancreas. J Pediatr 68, 215-221.
5. Fattom, A., Li, X., Cho, Y. H. & Burns, A. (1995). Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharide. Vaccine 13, 1288-1293.
6. Garner, C. V., DesJardins, D. & Pier, G. B. (1990). Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun 58, 1835-1842.
7. Govan, J. R. W. & Deretic, V. (1996). Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60, 539-574.
8. Johansen, H. K., Espersen, F., Cry, S. J., Hougen, H. P., Fomsgaard, A., Rygaard, J. & Hoiby, N. (1994). Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun 62, 3146-3155.
9. Johansen, H. K., Ougen, H. P., Cryz, S. J., Rygaard, J. & Hoiby, N. (1995). Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am J Respir Crit Care Med 152, 1337-1346.
10. Kashef, N., Behzadian-Nejad, Q., Najar-Peerayeh, S., Mousavi-Hosseini, K., Moazzeni, M., Rezvan, H. & Adibi-Motlagh, B. (2005). Preliminary investigation on the isolation of alginate produced by mucoid Pseudomonas aeruginosa. Ann Microbiol 55, 279-282.
11. Knutson, C. A. & Jeanes, A. (1986). A new modification of the carbazole analysis: application to heteropolysaccharides. Anal Biochem 24, 470-481.
12. Koch, C. & Høiby, N. (1993). Pathogenesis of cystic fibrosis. Lancet 341, 1065-1069.
13. Lakshman, R. & Finn, A. (2002). Meningococcal serogroup C conjugate vaccine. Expert Opin Biol Ther 2, 87-96.
14. Lowry, O. H., Rousebrough, N. J., Farr, A. L. & Randall, R. J. (1951). Protein measurement with Folin phenol reagent. J Biol Chem 193, 265-275.
15. Makela, P. H. (2003). Conjugate vaccines - a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 34, 249-253.
16. Mathee, K., Ciofu, O., Sternberg, C. & Lindum, P. W. (1999). Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145, 1349-1357.
17. Pedersen, S. S. (1992). Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS 100, 1-79.
18. Pedersen, S. S. & Kharazmi, A. (1990). Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun 58, 3363-3368.
19. Pelton, S. I., Dagan, R. & Gaines, B. M. (2003). Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 21, 1562-1571.
20. Peters, C. C., Tenbergen-Meekers, A. M. & Poolman, J. T. (1991). Effect of carrier priming in immunogenicity of polysaccharide-protein conjugate vaccine. Infect Immun 59, 3504-3510.
21. Pier, G. (2005). Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 4, 645-656.
22. Pier, G. B., Matthews, W. J. & Eardley, D. D. (1983). Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J Infect Dis 147, 494-503.
23. Pier, G. B., Small, G. J. & Warren, H. B. (1990). Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 249, 537-540.
24. Pier, G. B., DesJardin, D. & Grout, M. (1994). Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect Immun 62, 3972-3979.
25. Sherbrock-Cox, V., Russell, N. J. & Gacesa, P. (1984). The purification and chemical characterization of the alginate present in extracellular material produced by mucoid strains of Pseudomonas aeruginosa. Carbohydr Res 135, 147-154.
26. Sood, R. K., Fattom, A. & Pavliak, V. (1996). Capsular polysaccharide-protein conjugate vaccines. Research Focus 1, 381-387.
27. Theilacker, C., Coleman, F. T. & Mueschenborn, S. (2003). Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun 71, 3875-3884.
28. Watson, D. C., Robbins, J. B. & Szu, S. C. (1992). Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 60, 4679-4686.